BioArctic, founded in 2003, is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. BioArctic has a broad project portfolio of selective antibodies against various diseases of the central nervous system. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic has around 150 employees, is headquartered in Stockholm and BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap.